

*Meeting in radiation oncology – Brescia 2008*

# **Experimental models and future directions**

*Prof. Vincenzo Tombolini  
Giovanni Luca Gravina M.D.*

*Department of Experimental Medicine  
Division of Radiation Oncology  
University of L'Aquila*

## Experimental models and future directions in the study of solid tumors

<u>Cellular continuous lines</u>					
<u>Prostate</u> : PC3, DU145, LNCap, 22rv1, CWR22, CWR22R					
<u>Brain Tumors</u> : T98G, U373, U87MG, U251, SF539					
<u>Tumor Angiogenesis</u> : HUVEC, UMEC					
Tumoral Cell Inoculation	Model Aim	Effectiveness	Local growth	Bone Metastas.	Metastas. in other sites
<u>Subcutaneous</u>	Local growth in physiologic milieu	Good model to control tumor growth in vivo. Generally metastases are not observed	😊	✗	✗
<u>Intracardiac</u>	Extravasal Phase Diffusion on whole arterial system	Good rates of lumbar and lower limb metastases but poor rates of metastases in other sites. High technical difficulty with poor reproducibility	N.V.	😊	✗
<u>Directly Intrabone</u>	Local Growth in the sites of metastases	All the cases, by use of PC3, are positive. Other lines that don't metastasize bone can growth in the bone (LNCaP) with high rates.	😊	N.V.	✗

N.V. = non valuable



😊 = Good

✗ = absent

🌀 = occasional

## INOCULO CELLULE TUMORALI

Nave Mouse CD-1 nu/nuBR 4 week



**100.000 cells are injected in 100 µl of physiologic solution  
( That low cell number allows to simulate the real diffusion of tumor from his original site)**

**After 40 days (max), the animals are sacrificed.  
Radiographies (also after 30 days) , autopsies and  
Immuno-histochemical studies are performed**


# RADIOGRAPHIC VALUATION\* OF METASTASES

Radiography whole body



Digital Magnification

Normal view



Osteolytic lesions



\*Dedicate Machine: Faxitron

# VALUTAZIONE E RACCOLTA DELLE METASTASI

Autopsy and Examination of the animals  
Systematic Control of lungs, liver and  
adrenal glands



Evidence of metastatic lesions




Recovery of metastatic  
tissues







# INTRACARDIAC INJECTION



**MMP9 positive in bone metastases**

**B = bone marrow cells**  
**T = tumor cells**  
**E = cartilaginous epiphysis**



**Hematoxylin-eosin staining:**  
**T = Tumor**  
**O = Bone trabecula**  
**M = Bone marrow**

## INTRATIBIAL INJECTION

The extension of osteolytic lesions is much variable. We may observe lesions of varied extension, from well localized and like point areas to large and destroying metastases that invade surrounding tissues. The epithelial origin confirmation of tumor sub lines is performed by immuno-histochemical array of 8 and 18 cytokeratins.



macroscopic view




radiographic view

Enzymatic  
Digestion




ImmunoHistochemic of  
18 Cytokeratin

# Local tumor growth in vivo: Xenograft Model






# Local tumor growth in vivo: Xenograft Model



Morphologic  
Valuation



A: EGFR; B: HER2/neu; C: AKT; D: p-AKT; E: TRK-A; F: TRK-B

## Analysis Techniques of Tumor Tissues

**Injection Modality  
Tumor cells**

**Subcutaneous**

**Proteomic:**

Analysis of intracellular proteins(Western Blot , Dot blot), FACS (Apoptosis, cell cycle , autophagy, expression of membrane antinuclear antigens)  
Immunohistochemistry

**Gene Analysis :**

Analysis of messenger RNA (RT-PCR)  
DNA methylation

**Intracardiac**

**Proteomic:**

Analysis of intracellular proteins (Western Blot , Dot blot)  
Immunohistochemistry

**Gene Analysis :**

Analysis of messenger RNA (RT-PCR)  
DNA methylation

**Intrabone  
Directly**

**Proteomic:**

Analysis of intracellular proteins(Western Blot , Dot blot)  
Immunohistochemistry

**Gene Analysis :**

Analysis of messenger RNA (RT-PCR)  
DNA methylation

## **In progress Projects of translational researches**

### **Prostate Tumors**

**Study of Epigenetic drugs (HDAC e Demethylant) and Anti-target therapy like radio sensitizing in models of androgen dependent, independent and bone metastatic tumors**

### **Brain Tumors**

**Study of Epigenetic drugs (HDAC e Demethylant) and Anti-target like radio sensitizing in models of chemotherapy respondent and not respondent tumors**

### **Tumor Angiogenesis**

**The chance of Epigenetic drugs (HDAC e Demethylant) and Anti-target in tumor angiogenesis with and without Radiotherapy**



**Università Degli Studi Dell'Aquila**  
**Facoltà di Medicina e Chirurgia**

*Dipartimento di Medicina Sperimentale*  
*U.O. di Radioterapia*  
*Presidio Ospedaliero – S. Salvatore – L'Aquila*

*Prof. Vincenzo Tombolini*  
*Dott. Giovanni Luca Gravina*  
*Dott. Pierluigi Bonfili*  
*Dott. Mario Di Staso*

*Dipartimento di Medicina Sperimentale*  
*Laboratorio di Istopatologia*

*Prof. Anna Teti*  
*Dott. Nadia Rucci*

*Dipartimento di Medicina Sperimentale*  
*Laboratorio di Patologia Generale*

*Dott. Claudio Festuccia*

*Dipartimento di Medicina Sperimentale*  
*Laboratorio di Patologia Clinica*

*Prof. Vincenza Dolo*  
*Dott. Danilo Millimaggi*  
*Dott. Sandra D'Ascenzo*